Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy
- 2 December 2017
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 137 (1) , 67-75
Abstract
Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized patients for BRAF and NRAS mutations receiving conventional treatment. We investigated associations between outcomes [competing risk of local and distant brain failure (LF, DF) and overall survival (OS)] and clinical/pathological features of patients with known mutation status following initial treatment of MBM. Competing risk analysis was performed using the methods of Fine and Gray. We identified 235 patients with MBM diagnosed from 2005 to 2011. Mutation prevalence was BRAFnon-V600K 98 (42%), BRAFV600K 34 (14%), NRAS 43 (18%), and wild-type for both genes (WT) 60 (26%) patients. Six month cumulative incidence LF rates were 3% for combined SRS or surgery with adjuvant radiation, 18% for surgery, 18% for SRS, 60% for WBRT, and 67% for systemic therapy. On multivariate analysis, only mutation status and initial treatment type were found to be independent predictors of local control. As compared to WT, NRAS (HR 2.58, 95% CI 1.18–5.67, p = 0.02) and BRAFV600K (HR 2.83, 95% CI 1.23–6.47, p = 0.01) mutational status were statistically significant while BRAFnon-V600K status was not statistically significant (p = 0.23). Mutation status was not associated with DF or OS. BRAFV600K and NRAS mutation status predict increased LF following conventional treatments for MBM. These data can inform the design and interpretation of future MBM trials.Keywords
This publication has 33 references indexed in Scilit:
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2013
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain MetastasesJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Clinical Correlates of NRAS and BRAF Mutations in Primary Human MelanomaClinical Cancer Research, 2011
- Prognostic factors for survival in melanoma patients with brain metastasesCancer, 2010
- Genetic and morphologic features for melanoma classificationPigment Cell & Melanoma Research, 2010
- Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical featuresNeuro-Oncology, 2008
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999